Plant Name: Eleutherococcus gracilistylus
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.733E-13 | 6.290E-10 | CA1, CA12, CA2, CA4, CA6, CA7, CA9 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 3.460E-09 | 7.534E-06 | CYP2C19, CYP2C9, CYP3A4, NR1I2 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 5.681E-08 | 9.515E-05 | ALPI, CA1, CA12, CA2, CA4, CA6, CA7, CA9, NR1I2, PPARA, PPARG |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 9.054E-08 | 1.408E-04 | CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0065007; biological regulation | GO:0006919; activation of cysteine-type endopeptidase activity involved in apoptotic process | 2.634E-07 | 3.019E-04 | CASP1, CASP7, MAPT, PPARG, XDH |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 1.364E-06 | 1.291E-03 | CYP2C19, CYP2C9, CYP3A4, NR1I2, PTGS1 |
| MF | GO:0003824; catalytic activity | GO:0016705; oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen | 6.174E-06 | 4.201E-03 | CYP2C19, CYP2C9, CYP3A4, P4HB, PTGS1 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 7.207E-06 | 4.616E-03 | ALOX15, CYP2C19, CYP2C9, CYP3A4, XDH |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 8.482E-06 | 5.277E-03 | CA2, CA7 |
| BP | GO:0050896; response to stimulus | GO:0070482; response to oxygen levels | 8.734E-06 | 5.283E-03 | CASP1, HIF1A, P4HB, POLB, PPARA, PPARG |
| MF | GO:0003824; catalytic activity | GO:0051213; dioxygenase activity | 1.626E-05 | 8.581E-03 | ALOX15, KDM4E, P4HB, PTGS1 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.695E-05 | 8.581E-03 | CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.847E-19 | 4.021E-15 | CA1, CA12, CA14, CA2, CA4, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 4.919E-15 | 3.570E-11 | CA1, CA12, CA14, CA2, CA4, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 5.270E-19 | 3.478E-17 | CA12; CA1; CA2; CA4; CA7; CA6; CA9; CA14 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.417E-07 | 4.675E-06 | CYP2C9; ALOX15; CYP3A4; CYP2C19 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 3.202E-06 | 7.045E-05 | CYP2C9; ALOX15; CYP2C19; PTGS1 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 1.998E-05 | 3.297E-04 | CYP2C9; GAA; ALOX15; ALDH1A1; AKR1B1; ALPI; CYP2C19; CYP3A4; XDH; PTGS1 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 3.364E-05 | 4.441E-04 | CYP2C9; ALOX15; CYP2C19; PTGS1 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.667E-04 | 1.834E-03 | CYP2C9; ALDH1A1; CYP3A4 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.991E-04 | 1.877E-03 | CYP2C9; CYP3A4; CYP2C19 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 3.316E-04 | 2.736E-03 | CYP2C9; CYP3A4; CYP2C19 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 2.611E-03 | 1.567E-02 | CYP3A4; XDH |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 3.712E-03 | 2.042E-02 | CASP7; CASP1 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 1.116E-03 | 7.364E-03 | GAA; AKR1B1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 6.536E-04 | 4.793E-03 | CA2; CA4 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 6.449E-03 | 2.803E-02 | CYP2C9; CYP3A4 |
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 5.780E-03 | 2.803E-02 | PPARG; PPARA |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 6.110E-03 | 2.803E-02 | CA2; CYP3A4 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 6.795E-03 | 2.803E-02 | CASP7; CASP1 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 8.224E-03 | 3.193E-02 | XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | CASP1 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| NA: NA | Miosis during ocular surgery | NA | PTGS1 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | NR1I2 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | PTGS1 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; PTGS1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS1; PPARG |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | PTGS1 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | FFAR1; PPARG; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARG |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | PTGS1 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS1 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | FFAR1; AKR1B1; PPARG |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | PPARG |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT; PPARG; PPARG |
| C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A; CA1; CA9 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CASP1; AKR1B1 |
| NA: NA | Rheumatold arthritis | NA | PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1 |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9 |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARG |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | PTGS1 |
| NA: NA | Edema | NA | CA2 |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | CASP1 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PTGS1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; AKR1B1; PPARG |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; AKR1B1 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; CA9 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH |